Pyrrolo[1,2-a]quinoxalines: Insulin Mimetics that Exhibit Potent and Selective Inhibition against Protein Tyrosine Phosphatase 1B.,ChemMedChem

当前位置： X-MOL 学术 › ChemMedChem › 论文详情

Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)

Pyrrolo[1,2-a]quinoxalines: Insulin Mimetics that Exhibit Potent and Selective Inhibition against Protein Tyrosine Phosphatase 1B.
ChemMedChem ( IF 3.6 ) Pub Date : 2020-09-10 , DOI: 10.1002/cmdc.202000446
Javier García-Marín _{1,

2,

3} , Mercedes Griera _{2,

4} , Patricia Sánchez-Alonso ₁ , Bruno Di Geronimo ₅ , Francisco Mendicuti _{3,

6} , Manuel Rodríguez-Puyol _{2,

4} , Ramón Alajarín _{1,

2,

3} , Beatriz de Pascual-Teresa ₅ , Juan J Vaquero _{1,

2,

3} , Diego Rodríguez-Puyol _{2,

4}

Affiliation

PTP1B dephosphorylates insulin receptor and substrates to modulate glucose metabolism. This enzyme is a validated therapeutic target for type 2 diabetes, but no current drug candidates have completed clinical trials. Pyrrolo[1,2‐a]quinoxalines substituted at positions C1–C4 and/or C7–C8 were found to be nontoxic to cells and good inhibitors in the low‐ to sub‐micromolar range, with the 4‐benzyl derivative being the most potent inhibitor (0.24 μm). Some analogues bearing chlorine atoms at C7 and/or C8 kept potency and showed good selectivity compared to TCPTP (selectivity index >40). The most potent inhibitors behaved as insulin mimetics by increasing glucose uptake. The 4‐benzyl derivative inhibited insulin receptor substrate 1 and AKT phosphorylation. Molecular docking and molecular dynamics simulations supported a putative binding mode for these compounds to the allosteric α3/α6/α7 pocket, but inconsistent results in enzyme inhibition kinetics were obtained due to the high tendency of these inhibitors to form stable aggregates. Computational calculations supported the druggability of inhibitors.

中文翻译：

吡咯并[1,2-a]喹喔啉：对蛋白质酪氨酸磷酸酶1B表现出有效和选择性抑制的胰岛素模拟物。

PTP1B 使胰岛素受体和底物去磷酸化以调节葡萄糖代谢。这种酶是 2 型糖尿病的有效治疗靶点，但目前尚无候选药物完成临床试验。发现C1-C4 和/或 C7-C8 位取代的吡咯并[1,2- a ]喹喔啉对细胞无毒，并且在低至亚微摩尔范围内具有良好的抑制剂，其中 4-苄基衍生物是最有效的。强效抑制剂（0.24 μ m）。与 TCPTP 相比，在 C7 和/或 C8 处带有氯原子的一些类似物保持效力并显示出良好的选择性（选择性指数 >40）。通过增加葡萄糖摄取，最有效的抑制剂表现为胰岛素模拟物。4-苄基衍生物抑制胰岛素受体底物 1 和 AKT 磷酸化。分子对接和分子动力学模拟支持这些化合物与变构 α3/α6/α7 口袋的假定结合模式，但由于这些抑制剂形成稳定聚集体的高趋势，在酶抑制动力学方面获得了不一致的结果。计算计算支持抑制剂的成药性。

更新日期：2020-10-05

点击分享查看原文

点击收藏

阅读更多本刊最新论文本刊介绍/投稿指南11